Impact of Lycium barbarum polysaccharide on the expression of glucagon-like peptide 1 in vitro and in vivo.
Impact of Lycium barbarum polysaccharide on the expression of glucagon-like peptide 1 in vitro and in vivo.
复制标题
DOI：
10.1016/j.ijbiomac.2022.10.176
复制
发表时间：
2022-10
影响因子：
8.2
通讯作者：
Cong Zhao;He Zhao;Chun-Cheng Zhang;Xiao-Hui Yang;Kang Chen;Yang Xue;Qian-Ru Li;Shuying Deng;H. Cai
中科院分区：
文献类型：
--
作者：
Cong Zhao;He Zhao;Chun-Cheng Zhang;Xiao-Hui Yang;Kang Chen;Yang Xue;Qian-Ru Li;Shuying Deng;H. Cai
几项研究显示了枸杞多糖（LBP）在糖尿病动物和2型糖尿病（T2DM）患者中的疗效。然而，LBP缓解T2DM的机制基于胰高血糖素样肽1（GLP 1）尚未得到适当的阐明。GLP 1是一种重要的肽，在血糖稳态中起作用。钠/葡萄糖协同转运蛋白1（SGLT 1）的抑制可导致GLP 1释放的净增加。我们发现LBP可以降低SGLT 1的表达。因此，LBP对GLP 1第一和第二时相分泌的影响在体外使用STC 1细胞和在糖尿病小鼠体内进行了系统的评估。LBP可通过刺激体外钙离子流入和抑制体内α-葡萄糖苷酶活性来诱导GLP 1的第一时相分泌。通过调节Wnt/β-catenin和cAMP/Epac途径调节Gcg基因表达，以及抑制α-葡萄糖苷酶活性，负责GLP 1的第二相分泌。LBP可刺激GLP 1分泌，但LBP激活的二肽基肽酶4（DPP4）可抵消GLP 1分泌的第二相。因此，我们建议考虑同时使用LBP和DPP4抑制剂来刺激缓慢，连续的GLP 1分泌。进一步的研究是必要的深入机制的信息。
Several studies showed the efficacy of Lycium barbarum polysaccharide (LBP) in diabetic animals and patients with type 2 diabetes mellitus (T2DM). However, the mechanism of LBP in alleviating T2DM based on glucagon-like peptide 1 (GLP1) has not been suitably elucidated. GLP1 is an important peptide that plays a role in blood glucose homeostasis. Inhibition of sodium/glucose cotransporter 1 (SGLT1) can result in a net increase in GLP1 release. We found that LBP could reduce SGLT1 expression. Thus, the effects of LBP on the first- and second-phase secretion of GLP1 were systematically assessedin vitrousing STC1 cells andin vivousing diabetic KKAymice. LBP could induce the first-phase secretion of GLP1 by stimulating calcium ion influxin vitroand by inhibiting alpha-glucosidase activityin vivo. Regulation ofGcggene expression by modulating the Wnt/β-catenin and cAMP/Epac pathways, as well as inhibition of alpha-glucosidase activity, was responsible for the second-phase secretion of GLP1. LBP could stimulate GLP1 secretion; however, dipeptidyl peptidase 4 (DPP4) activated by LBP might offset the second-phase secretion of GLP1. Thus, we suggest considering the simultaneous use of LBP and a DPP4 inhibitor to stimulate slow, continuous GLP1 secretion. Further studies are warranted for in-depth mechanistic information.